News

Reset
  • 09/07/2019

    Arecor signs a new formulation evaluation agreement with an existing partner, a major global pharmaceutical company

  • 07/05/2019

    Proactive Investors INTERVIEW with Sarah Howell

  • 07/05/2019

    First Patient Dosing In Phase I Clinical Trial 7May2019

  • 03/05/2019

    Arecor Signs A New Multi-Product Collaboration With A Major Global Pharmaceutical Company

  • 27/03/2019

    Arecor listed in Business Weekly’s ‘Killer50’

  • 20/03/2019

    ARECOR RECEIVES REGULATORY APPROVAL TO INITIATE PHASE I CLINICAL TRIAL FOR ULTRA-RAPID ACTING INSULIN PRODUCT

  • 11/03/2019

    PROACTIVEINVESTORS interview with CEO Sarah Howell re Arecor’s strengthening of its team with the appointment of an experienced Chief financial Officer

  • 11/03/2019

    Arecor Appoints Chief Financial Officer

  • 13/02/2019

    Super-fast-acting Prandial insulin product receives £0.5m innovate UK boost

  • 21/01/2019

    SCRIP Feature article on Arecor entitled: “Standing On The Shoulders Of Giants: Could Arecor Enter The Race To Revolutionize Diabetes?”

  • 09/01/2019

    ARECOR TO PARTICIPATE AT PEPTALK 2019’s PROTEIN SCIENCE WEEK IN SAN DIEGO, CA, USA

  • 04/01/2019

    ARECOR ANNOUNCES CLINICAL TRIALS APPLICATION TO CONDUCT A PHASE 1 CLINICAL TRIAL OF ITS ULTRA RAPID ACTING INSULIN PRODUCT